cancer sequencing
Although the firm did not provide preliminary financial results for 2024, CEO Chris Smith reaffirmed previous guidance of revenues between $655 million and $667 million.
Pillar Biosciences, AstraZeneca Partner on Liquid Biopsy Testing in Europe
AstraZeneca has partnered with several other firms on liquid biopsies, including Angle, Sophia Genetics, IMBdx, and Guardant Health.
Cancer Sequencing Labs, Advocacy Groups Partner to Increase Genetic Testing Access
The newly launched INTERACT coalition said it will try to press medical and industry guidelines to keep pace with evidence surrounding inherited cancer risk.
Foundation Medicine, Natera Launch ctDNA Therapy Response Assay With Medicare Coverage
The tissue-informed ctDNA assay is available to US physicians and is eligible for coverage through both the MolDx and New York's CLEP programs.
Realm IDx Cancer Genome Profiling Test Gets National Health Coverage in Japan
The company said it will launch the test, which combines DNA and RNA analysis, for research use only in markets outside of Japan.